Glucocorticoids are widely used in the management of autoimmune, inflammatory and neoplastic conditions. However, they are associated with significant metabolic effects, including steroid-induced diabetes (SID). SID is typically diagnosed using general criteria for type 2 diabetes, which may be inadequate due to the unique glycemic profile often seen in SID, where postprandial hyperglycemia predominates. This research aims to explore the diagnostic value of CGM during steroid therapy and identify risk factors for SID This is a prospective observational study (n=250) enrolling adults initiating glucocorticoid therapy. Participants will undergo 14-day continuous glucose monitoring (CGM) to assess predictive factors and glycemic profile.
Approximately 250 patients hospitalised at Warsaw University Hospital will be enrolled. Baseline data collection includes medical history, anthropometry, HbA1c, and basic biochemical tests. CGM sensors will be applied. The glycemic profile will be monitored for 14 days using the CGM system. If time spent above 140 mg/dL exceeds 10%, capillary glucose testing will be used to confirm diabetes based on established clinical guidelines
Study Type
OBSERVATIONAL
Enrollment
250
Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Warsaw, Warsaw, Poland
Diagnosis of diabetes
diagnosis of steroid-induced diabetes based on fasting blood glucose 2 times above 126 mg/dl and/or HbA1c\>6.5% and/or blood glucose above 200 mg/dl
Time frame: From enrollment to the end of the observation at 2 weeks
Glycemic Target
Assessment of Time in range (70-180 mg/dl)
Time frame: From enrollment to the end of the observation at 2 weeks
Time above 140 mg/dL for ≥10% of the day
More than 10% of the day spend in range of glucose levels above 140 mg/dl is associated with significantly increased risk of diabetes
Time frame: From enrollment to the end of the observation at 2 weeks
Hypoglycaemia Episodes
Assessment of Time below range (\<70 mg/dl) through Continuous Glucose Monitoring System
Time frame: From enrollment to the end of the observation at 2 weeks
Glycemic profile
Assessment of glycemic profile through CGM sensor: Glucose monitoring index
Time frame: From enrollment to the end of the observation at 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.